Chinese Regulators, Police Intensify Investigation Of Vaccine Producer For Possible Malfeasance, Cover-up
This article was originally published in The Pink Sheet Daily
Simcere Pharmaceutical has revealed that certain personnel at recently acquired vaccine producer Jiangsu Yanshen are under investigation for possible attempts to cover up lapses in good manufacturing practice standards that led to the release of substandard rabies vaccine doses in 2008.
You may also be interested in...
BEIJING - Just weeks after acquiring a controlling equity stake in vaccine developer Jiangsu Yanshen, leading Chinese drug maker Simcere Pharmaceutical is pressing its new subsidiary to freeze production and replace two top executives that may have been responsible for lapses in good manufacturing practice standards at the vaccine facility
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.